Article Details

Tafamidis confers 5-year survival benefit in transthyretin amyloid cardiomyopathy - Healio

Retrieved on: 2021-12-28 18:02:19

Tags for this article:

Click the tags to see associated articles and topics

Tafamidis confers 5-year survival benefit in transthyretin amyloid cardiomyopathy - Healio. View article details on hiswai:

Excerpt

Elliott reports consulting for AstraZeneca, Novo Nordisk and Pfizer. Please see the study for all other authors' relevant financial disclosures.

Article found on: www.healio.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up